Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials • Medical Devices & Mechanical Engineering
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Macquarie University is currently managing 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 5 distinct examiners, ensuring that each individual application is subject to an independent review process. This lack of examiner overlap means that the university must engage with 5 different sets of examination criteria and feedback styles. For the legal team, this necessitates a customized approach for each case rather than a centralized negotiation strategy with a single official.
The portfolio's activity is spread across 5 distinct art units, reflecting a diverse range of technical subject matter within the biotechnology field. This distribution across 5 distinct art units can lead to varying timelines and procedural expectations for the 5 pending office actions. MALAMUD, DEBORAH LESLIE is noted as the busiest examiner for the portfolio, currently overseeing 1 pending office action. Because this busiest examiner only handles a single case, the workload is evenly distributed among the assigned officials.
The presence of multiple examiners and art units suggests that the university is dealing with a broad array of intellectual property challenges. Practitioners should be prepared to maintain consistency in technical arguments across these different venues to avoid conflicting statements. With MALAMUD, DEBORAH LESLIE managing 1 pending office action, the remaining files are each under the jurisdiction of other examiners, requiring a broad allocation of resources to manage the active workload effectively.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| §112 only | 1 (20%) |
| Multi-statute (no §101) | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MALAMUD, DEBORAH LESLIE | 1 | 78.2% | +9.6% |
| BEANE, RANDALL L | 1 | 32.9% | +36.2% |
| FORSYTH, PAUL ALAN | 1 | 69.8% | +2.2% |
| NOBLE, MARCIA STEPHENS | 1 | 67.2% | +39.5% |
| FERGUSON, JALISA HOLMES | 1 | 62.2% | +41.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18558006 | A SURGICAL IMPLANT | MALAMUD, DEBORAH LESLIE | 30d |
| 18268203 | TREATMENT OF GLAUCOMA | BEANE, RANDALL L | — |
| 17787007 | ALUMINOSILICATE GLASS | FORSYTH, PAUL ALAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18268203 | TREATMENT OF GLAUCOMA | BEANE, RANDALL L | — |
| 17754597 | MODULATION OF CELLULAR VIABILITY | NOBLE, MARCIA STEPHENS | — |
| 17754135 | TREATMENT OF DEMENTIA | FERGUSON, JALISA HOLMES | — |
| Art Unit | Apps |
|---|---|
| 3792 | 1 |
| 1654 | 1 |
| 1731 | 1 |
| 1632 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18558006 | A SURGICAL IMPLANT | MALAMUD, DEBORAH LESLIE | 3792 | §102§103 | Non-Final OA | 30d | Pending | Oct 30, 2023 |
| 18268203 | TREATMENT OF GLAUCOMA | BEANE, RANDALL L | 1654 | §103§112 | Non-Final OA | — | Pending | Jun 16, 2023 |
| 17787007 | ALUMINOSILICATE GLASS | FORSYTH, PAUL ALAN | 1731 | §102§103 | Non-Final OA | — | Pending | Jun 24, 2022 |
| 17754597 | MODULATION OF CELLULAR VIABILITY | NOBLE, MARCIA STEPHENS | 1632 | §112 | Final Rejection | — | Pending | Apr 06, 2022 |
| 17754135 | TREATMENT OF DEMENTIA | FERGUSON, JALISA HOLMES | 1626 | §103 | Non-Final OA | — | Pending | Mar 24, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMacquarie University has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Deborah Leslie Malamud has the most, with 1 of Macquarie University's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
